| Document and Entity Information - shares | 9 Months Ended | |
| Mar. 31, 2017 | Apr. 10, 2017 | |
| Document and Entity Information [Abstract] | ||
| Entity Registrant Name | Green Meadow Products, Inc. | |
| Entity Central Index Key | 1,557,340 | |
| Document Type | 10-Q | |
| Document Period End Date | Mar. 31, 2017 | |
| Amendment Flag | false | |
| Current Fiscal Year End Date | --06-30 | |
| Entity Well-known Seasoned Issuer | No | |
| Entity Voluntary Filers | No | |
| Entity Current Reporting Status | Yes | |
| Document Fiscal Year Focus | 2,017 | |
| Document Fiscal Period Focus | Q3 | |
| Entity Filer Category | Smaller Reporting Company | |
| Entity Common Stock, Shares Outstanding | 52,944,500 |
| CONDENSED BALANCE SHEETS (UNAUDITED) - USD ($) | Mar. 31, 2017 | Jun. 30, 2016 |
| Current Assets | ||
| Cash | $ 1,974 | $ 8,977 |
| Accounts Receivable | 12,100 | 0 |
| Total Current Assets | 14,074 | 8,977 |
| Other Assets | ||
| Web development costs, net of amortization of $7,750 and $5,500 respectively. | 7,250 | 9,500 |
| Other intangible assets, net of amortization of $4,335 and $3,528 respectively. | 6,415 | 7,222 |
| Total Assets | 27,739 | 25,699 |
| Current Liabilities | ||
| Accounts Payable | 7,000 | 5,000 |
| Total Current Liabilities | 7,000 | 5,000 |
| Total Liabilities | 7,000 | 5,000 |
| Stockholders' Equity | ||
| Common stock $0.001 par value 75,000,000 shares authorized 52,944,500 - shares issued and outstanding at March 31, 2017 and June 30, 2016 | 52,945 | 52,945 |
| Additional paid-in-capital | 505 | 505 |
| Accumulated Earnings (Deficit) | (32,711) | (32,751) |
| Total Stockholders' Equity | 20,739 | 20,699 |
| Total Liabilities and Stockholders' Equity | $ 27,739 | $ 25,699 |
| CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($) | Mar. 31, 2017 | Jun. 30, 2016 |
| Statement of Financial Position [Abstract] | ||
| Accumulated Amortization - Web Development Costs | $ 7,750 | $ 5,500 |
| Accumulated Amortization - Other Intangible Assets | $ 4,335 | $ 3,528 |
| Common stock par value | $ 0.001 | $ 0.001 |
| Common stock shares authorized | 75,000,000 | 75,000,000 |
| Common stock shares issued | 52,944,500 | 52,944,500 |
| Common stock shares outstanding | 52,944,500 | 52,944,500 |
| CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) | 3 Months Ended | 9 Months Ended | ||
| Mar. 31, 2017 | Mar. 31, 2016 | Mar. 31, 2017 | Mar. 31, 2016 | |
| Revenue | ||||
| Sub license agreements | $ 0 | $ 0 | $ 12,200 | $ 15,000 |
| Sales | 12,000 | 6,000 | 12,000 | 9,360 |
| Total Revenue | 12,000 | 6,000 | 24,200 | 24,360 |
| Cost of Goods Sold | ||||
| Cost of goods | 7,000 | 0 | 7,000 | 2,000 |
| Total cost of Goods Sold | 7,000 | 0 | 7,000 | 2,000 |
| Gross profit | 5,000 | 6,000 | 17,200 | 22,360 |
| Operating Expenses | ||||
| Professional fees | 0 | 9,331 | 9,022 | 27,728 |
| Amortization | 1,019 | 1,019 | 3,057 | 3,057 |
| Advertising | 4,500 | 0 | 4,500 | |
| Consulting | 0 | 0 | 0 | 11,000 |
| Marketing-Video Expense | 575 | 5,000 | 575 | 5,000 |
| Other fees | 3 | 3 | 6 | 784 |
| Total Operating Expenses | 6,097 | 15,353 | 17,160 | 47,569 |
| Income (loss) before income taxes | (1,097) | (9,353) | 40 | (25,209) |
| Income taxes | 0 | (1,403) | 0 | (3,781) |
| Net Income (loss) | $ (1,097) | $ (7,950) | $ 40 | $ (21,428) |
| Basic and Diluted Income (Loss) Per Share | $ 0 | $ 0 | $ 0 | $ 0 |
| Weighted Average of Common Shares Outstanding - Basic and Diluted | 52,944,500 | 52,944,500 | 52,944,500 | 52,944,500 |
| CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) | 9 Months Ended | |
| Mar. 31, 2017 | Mar. 31, 2016 | |
| Cash Flows from Operating Activities | ||
| Net Income (loss) | $ 40 | $ (21,428) |
| Adjustments to Reconcile Net Income (Loss) To Net Cash Provided by (Used In) Operating Activities: | ||
| Amortization expense | 3,057 | 3,057 |
| Changes in operating assets and liabilities | ||
| Accounts receivable | (12,100) | 0 |
| Accounts payable | 2,000 | (298) |
| Income tax Payble | 0 | (3,781) |
| Net Cash Provided by (Used in) Operating Activities | (7,003) | (22,450) |
| Cash Flows from Investing Activities | ||
| Website development costs | 0 | 0 |
| Net Cash used in Investing Activities | 0 | 0 |
| Cash Flows from Financing Activities | ||
| Proceeds from sale of common stock | 0 | 0 |
| Net Cash Provided by (Used in) Financing Activities | 0 | 0 |
| Increase (decrease) in Cash | (7,003) | (22,450) |
| Cash at Beginning of Period | 8,977 | 33,162 |
| Cash at End of Period | 1,974 | 10,712 |
| Supplemental disclosure | ||
| Cash paid for interest | 0 | 0 |
| Cash paid for income taxes | $ 0 | $ 0 |
| NATURE OF OPERATIONS | 9 Months Ended |
| Mar. 31, 2017 | |
| Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
| NATURE OF OPERATIONS | Note 1 – NATURE OF OPERATIONS Green Meadow Products, Inc. ("the Company", "GMP", "we", "us" or "our") was incorporated under the laws of the State of Wyoming on June 22, 2012. The Company's goal from the outset was to establish itself as a "Green" Company where our focus would be on products that were environmentally friendly. Our current focus is on the sales of licensing rights to our Green Meadow PR formula and the manufacturing and sales of our Green Meadow PR formula, both of which are organic products, as well as the manufacturing and sales of our PawPal product and our recently acquired stress relief formula. We have also tested and sold organic dog treats which contain our pain relief formula and are currently seeking funding sources for the manufacturing of the dog treats as well as our pain relief product for dogs. In the three months ended March 31, 2017 we made a decision to review additional potential products for marketing and distribution in what we consider to be the "Green Sector" or "environmentally friendly". As a result we acquired seven Optec Fuel maximizer devices for vehicles in March of 2017 for testing; comprised of 2 HD Optec Fuel Maximizers, 2 Intermediate Optec Fuel Maximizers, 1 Optec Fuel Maximizer for gas passenger cars, 1 Optec Fuel Maximizer for diesel passenger cars. The Optec Fuel maximizer is an on demand technology designed for computer controlled gasoline and diesel engines for improved fuel efficiency while simultaneously reducing harmful emissions. We believe that the technology can reduce greenhouse gas emissions which in turn could conceivably aid in making the air much healthier in our cities. Should the Company's testing of the devices prove to meet the claims of the manufacturer we may enter into future discussions with Optec for potential licensing rights for the devices. ( For further information on Optec Products acquired-www.optecmpg.com |
| SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 9 Months Ended |
| Mar. 31, 2017 | |
| Accounting Policies [Abstract] | |
| SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | Note 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES A summary of the significant accounting policies applied in the preparation of the accompanying financial statements follows. BASIS OF PRESENTATION The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. They do not include all information and footnotes necessary for a fair presentation of financial position, results of operations and cash flows in conformity with U.S. GAAP for complete financial statements. Certain information and note disclosures normally included in audited financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to make the information not misleading. In the opinion of management, all adjustments (consisting of normal recurring adjustments and accruals) considered necessary for a fair presentation of the results of operations for the period presented have been included in the interim period. The operating results for the three and nine-month period ended March 31, 2017 are not necessarily indicative of the results to be expected for the entire year ending June 30, 2017 or for any future period. These unaudited condensed financial statements and notes should be read in conjunction with the financial statements and related notes contained in the Company's Annual Report on Form 10-K for the year ended June 30, 2016. RECLASSIFICATION Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. CUSTOMER AND PURCHASE CONCENTRATION During the quarter ended March 31, 2017 we had sales of Optec Products of $12,000 on March 10, 2017 with 60 day terms which accounted for 100% of our revenue of which $1,000 was paid in March. During the nine months ended March 31, 2017 we had sales of Optec Products of $12,000 which accounted for 49% of our revenue and sub license agreements of $12,200 which accounted for 51% of our revenue; During the quarter ended March 31, 2016 we charged a fee for assisting with a video for pain relief for dogs of $6,000 which accounted for 100% of our revenue; During the nine months ended March 31, 2016 we had sales of $24,360 from three customers: $10,000 from Mountain High for sales of our dog treat formula, which equates to 40% of sales; $5,000 from Wholesale for you for purchase of pain relief products for dogs, which equates to 21% of sales; $3,360 in Swap Meet sales of Petaprin the pain relief product for dogs which equates to 14% of sales and $6,000 for a fee for assisting with a video for pain relief for dogs which equates to 25% of sales. NET INCOME (LOSS) PER SHARE OF COMMON STOCK The Company computes net income (loss) per share in accordance with ASC 105, "Earnings per Share" which requires presentation of both basic and diluted earnings per share on the face of the statement of operations. Basic income (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted loss per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive. The Company has no potentially dilutive debt or equity instruments issued and outstanding during the quarters ended March 31, 2017 or 2016. RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and does not believe the future adoption of any such pronouncements may be expected to cause a material impact on our financial condition or the results of its operations. |
| GOING CONCERN | 9 Months Ended |
| Mar. 31, 2017 | |
| - GOING CONCERN [Abstract] | |
| GOING CONCERN | Note 3– GOING CONCERN The financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. This raises substantial doubt about the Company's ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain adequate capital, it could be forced to cease operations. In order to continue as a going concern, the Company will need, among other things, additional capital resources. The Company is contemplating conducting an offering of its debt or equity securities to obtain additional operating capital. The Company is dependent upon its ability, and will continue to attempt to secure equity and/or debt financing. There are no assurances that the Company will be successful and without sufficient financing it would be unlikely for the Company to continue as a going concern. |
| REVENUE RECOGNITION | 9 Months Ended |
| Mar. 31, 2017 | |
| Notes to Financial Statements | |
| REVENUE RECOGNITION | Note 4 – REVENUE RECOGNITION The Company recognizes revenue in accordance with Accounting Standards Codification No. 605, "Revenue Recognition" ("ASC-605"), ASC-605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectibility is reasonably assured. Determination of criteria (3) and (4) are based on management's judgments regarding the fixed nature of the selling prices of the products delivered and the collectibility of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. The Company will defer any revenue for which the product has not been delivered or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered or no refund will be required. The Company's revenues have been generated primarily through sublicense and distribution agreements related to our Paw Pal product and our pain relief products. In the three months ended March 31, 2017 we acquired 7 Optec Fuel maximizer devices for vehicles for testing and for resale. The terms of these agreements generally consist solely of upfront, nonrefundable payments for licensing and distribution rights. Revenues from non-refundable licensing and distribution fees are recognized upon receipt of the payment if the license has stand-alone value and we do not have ongoing involvement or obligations. For the year ended June 30, 2016 and the nine period ended March 31, 2017, all license payments met the above criteria or in the case of one contract, the only continuing involvement was to sell our products to the distributor at pricing that is consistent with market transactions, thereby allowing for the recognition of revenue for the licensing and distribution arrangements upon receipt. When non-refundable license fees do not meet this criteria, the license revenues are recognized over the expected period of performance. We periodically review for any expected period of substantial involvement under the agreements that provide for non-refundable up-front payments and license fees. If ever applicable, we will adjust the amortization periods when appropriate to reflect changes in assumptions relating to the duration of our expected involvement. |
| INCOME TAXES | 9 Months Ended |
| Mar. 31, 2017 | |
| Income Tax Disclosure [Abstract] | |
| INCOME TAXES | Note 5 - INCOME TAXES The provision for income taxes differs from the amount computed by applying the statutory federal income tax rate to income before provision for income taxes. The sources and tax effects of the differences for the periods presented are as follows: For the three month and nine month periods ended March 31, 2017, we did not recognize a tax expense, due to utilization of net operating loss carryforwards. |
| SUBSEQUENT EVENTS | 9 Months Ended |
| Mar. 31, 2017 | |
| Subsequent Events [Abstract] | |
| SUBSEQUENT EVENTS | Note 6 – SUBSEQUENT EVENTS Management has reviewed events between March 31, 2017 to the date that the financials were issued, and there were no significant events identified for disclosure. |
| SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 9 Months Ended |
| Mar. 31, 2017 | |
| Accounting Policies [Abstract] | |
| BASIS OF PRESENTATION | BASIS OF PRESENTATION The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. They do not include all information and footnotes necessary for a fair presentation of financial position, results of operations and cash flows in conformity with U.S. GAAP for complete financial statements. Certain information and note disclosures normally included in audited financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to make the information not misleading. In the opinion of management, all adjustments (consisting of normal recurring adjustments and accruals) considered necessary for a fair presentation of the results of operations for the period presented have been included in the interim period. The operating results for the three and nine-month period ended March 31, 2017 are not necessarily indicative of the results to be expected for the entire year ending June 30, 2017 or for any future period. These unaudited condensed financial statements and notes should be read in conjunction with the financial statements and related notes contained in the Company's Annual Report on Form 10-K for the year ended June 30, 2016. |
| RECLASSIFICATION | RECLASSIFICATION Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. |
| CUSTOMER AND PURCHASE CONCENTRATION | CUSTOMER AND PURCHASE CONCENTRATION During the quarter ended March 31, 2017 we had sales of Optec Products of $12,000 on March 10, 2017 with 60 day terms which accounted for 100% of our revenue of which $1,000 was paid in March. During the nine months ended March 31, 2017 we had sales of Optec Products of $12,000 which accounted for 49% of our revenue and sub license agreements of $12,200 which accounted for 51% of our revenue; During the quarter ended March 31, 2016 we charged a fee for assisting with a video for pain relief for dogs of $6,000 which accounted for 100% of our revenue; During the nine months ended March 31, 2016 we had sales of $24,360 from three customers: $10,000 from Mountain High for sales of our dog treat formula, which equates to 40% of sales; $5,000 from Wholesale for you for purchase of pain relief products for dogs, which equates to 21% of sales; $3,360 in Swap Meet sales of Petaprin the pain relief product for dogs which equates to 14% of sales and $6,000 for a fee for assisting with a video for pain relief for dogs which equates to 25% of sales. |
| NET INCOME (LOSS) PER SHARE OF COMMON STOCK | NET INCOME (LOSS) PER SHARE OF COMMON STOCK The Company computes net income (loss) per share in accordance with ASC 105, "Earnings per Share" which requires presentation of both basic and diluted earnings per share on the face of the statement of operations. Basic income (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of outstanding common shares during the period. Diluted loss per share gives effect to all dilutive potential common shares outstanding during the period. Dilutive loss per share excludes all potential common shares if their effect is anti-dilutive. The Company has no potentially dilutive debt or equity instruments issued and outstanding during the quarters ended March 31, 2017 or 2016. |
| RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS | RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and does not believe the future adoption of any such pronouncements may be expected to cause a material impact on our financial condition or the results of its operations. |
| SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) | 3 Months Ended | 9 Months Ended | ||
| Mar. 31, 2017 | Mar. 31, 2016 | Mar. 31, 2017 | Mar. 31, 2016 | |
| Licensing Revenue | $ 12,000 | $ 6,000 | $ 24,200 | $ 24,360 |
| Assisting Fees [Member] | ||||
| Licensing Revenue | $ 6,000 | $ 6,000 | ||
| Percent of Licensing Revenue | 100.00% | 25.00% | ||
| Mountain High [Member] | ||||
| Licensing Revenue | $ 10,000 | |||
| Percent of Licensing Revenue | 40.00% | |||
| Wholesale [Member] | ||||
| Licensing Revenue | $ 5,000 | |||
| Percent of Licensing Revenue | 21.00% | |||
| Swap Meet [Member] | ||||
| Licensing Revenue | $ 3,360 | |||
| Percent of Licensing Revenue | 14.00% | |||
| Optec Products [Member] | ||||
| Licensing Revenue | $ 12,000 | $ 24,200 | ||
| Percent of Licensing Revenue | 100.00% | 100.00% | ||
| Revenue [Member] | ||||
| Licensing Revenue | $ 12,000 | |||
| Percent of Licensing Revenue | 49.00% | |||
| Sub Licensing Agreements [Member] | ||||
| Licensing Revenue | $ 12,200 | |||
| Percent of Licensing Revenue | 51.00% | |||
| INCOME TAXES (Details) - USD ($) | 3 Months Ended | 9 Months Ended | ||
| Mar. 31, 2017 | Mar. 31, 2016 | Mar. 31, 2017 | Mar. 31, 2016 | |
| Effective Income Tax Rate Reconciliation, Tax Credit, Percent [Abstract] | ||||
| Income tax expense (benefit) | $ 0 | $ 1,403 | $ 0 | $ 3,781 |
